Replies to post #493 on Genocea Biosciences Inc (GNCAQ)

[NY1972]

I thought their P1 dose was too low. Clonal works in blood cancers with linear genetic drift, not solid cancers. Playing tug of war with cancer requires a division of 60/40 CD4/CD8.

Following the first disease evaluation by scan six-weeks post cNeT infusion, stable disease was observed in four out of the six patients and progressive disease in two. One patient had a reduction in the size of two of their four tumor lesions by approximately 55% and 90%. Engraftment data for our cNeTs are currently available from four patients, with evidence of engraftment in two. This tumor lesion reduction and the highest engraftment was in the patient who received the highest cell dose.

[NY1972]

I doubt that P1 data is worth much. Achilles should target blood cancers to get better ORR.

[jondoeuk]

Much earlier than I thought http://www.globenewswire.com/fr/news-release/2021/03/01/2184790/0/en/Achilles-Therapeutics-Announces-Filing-of-Registration-Statement-for-Proposed-Initial-Public-Offering-in-the-United-States.html

https://www.sec.gov/Archives/edgar/data/1830749/000119312521063774/d19910df1.htm

[jondoeuk]

Poster (ACHL) https://ir.achillestx.com/static-files/eefe8e60-023f-4beb-9681-44e4451032bc

[jondoeuk]

This year there will be interim data from ten patients, first patient will dosed in the combo trials, they will enrol the first patient in the US, an IND will be filed for HNSCC, and Catapult manufacturing will come on-line.

In the first half of next year the first patient will dosed with higher doses, there will be interim data from the combo trials, they will initiate a tumour archiving program and establish a US R&D facility.

For the second half, more interim data from those given higher doses, they will incorporate closed automation tech and start a trial in the follow-on indication.

As for the gene editing tech (undisclosed), it may be used to prevent the expression of immune checkpoints expressed, add molecules to increase trafficking to tumours, and/or deliver inflammatory mediators into the TME, including but not limited to cytokines, soluble immune-regulatory receptors and/or ligands.